

For Immediate Release

Trendlines and B. Braun Enter into Memorandum of Understanding for investment in Trendlines Medical Singapore

- **Trendlines Medical Singapore will focus on the incubation and commercialization of early-stage healthcare companies with a focus on Singapore and the region**
- **B. Braun will invest in Trendlines Medical Singapore and along with Trendlines, support the development of portfolio companies, and actively consider follow-on investment opportunities in portfolio companies**
- **Ms. Anna Maria Braun, President of B. Braun Asia Pacific, will join Trendlines Medical Singapore's board of directors**
- **The first medical incubator established by an Israeli company in Singapore and Trendlines' first incubator outside of Israel**

Singapore, 8 September 2016 – The Trendlines Group Ltd. (“**Trendlines**”), an Israeli company listed on Catalist of the Singapore Exchange focused on establishing and developing innovation-based companies in the medical and agricultural fields, and B. Braun Melsungen AG (“**B. Braun**”), one of the world's leading providers of healthcare solutions with 56,000 employees in 64 countries, jointly announced today that they have entered into a Memorandum of Understanding (“**MOU**”), under which, B. Braun and Trendlines will jointly invest in Trendlines Medical Singapore Pte. Ltd. (“**Trendlines Medical Singapore**”), both parties will appoint members to Trendlines Medical Singapore's board of

directors and investment committee, and B. Braun will advise on market needs and technical and commercial matters.

The incorporation of Trendlines Medical Singapore was previously announced on the Singapore Exchange on 18 July 2016. Trendlines Medical Singapore will be a platform for the investment in and incubation of early-stage healthcare companies with a focus on Singapore and the region.

B. Braun, as a co-founder of Trendlines Medical Singapore, will support the development of the portfolio companies by providing its expertise in the medical technology field, including technological development, regulatory, medical & scientific affairs, and marketing and sales.

Mr Eric Loh has been appointed chief executive of Trendlines Medical Singapore. Mr. Loh has more than 20 years of experience in the medical device industry. Mr. Loh formerly served as senior vice-president at Biosensors International, an early-stage cardiovascular device company listed in Singapore, where he led corporate development and sales and marketing and commercialized Biosensors' products in the fast-growing Chinese market and other Asia Pacific markets. He was also involved in Biosensor's initial public offering ("IPO") on the Singapore Exchange and in merger and acquisition transactions that advanced the company.

Ms. Anna Maria Braun, a deputy member of the Management Board of B. Braun, will become a member of the board of directors of Trendlines Medical Singapore. Ms. Braun is the President of B. Braun Asia Pacific, responsible for the business of the global pharmaceutical and medical technology company in the region, including one of the group's largest manufacturing sites in the world with over 7,000 employees in Penang, Malaysia. Ms. Braun will share her healthcare industry expertise by providing advice and support to Trendlines Medical Singapore and its portfolio of companies, in areas related to B. Braun's activities.

Commenting on the establishment of Trendlines Medical Singapore, Mr. D. Todd Dollinger, Chairman and CEO of Trendlines, said, *"We announced our plan to establish an incubator in Singapore as part of our international expansion strategy at the time of the IPO on the Singapore Exchange. We are pleased that B. Braun, a strategic partner of Trendlines since our IPO, will participate in the development of the incubator and will enhance our collaboration in the global healthcare industry. The combination of Trendlines' experience in business incubation,*

B. Braun's knowledge and industry insights and financial strength, gives strong support to the launch of Trendlines Medical Singapore."

Mr. Eric Loh, CEO of Trendlines Medical Singapore, added, *"Trendlines Medical Singapore is our first incubator outside of Israel. Singapore offers a conducive environment for innovation commercialization, with a strategic location as a business hub in Asia, generation of innovative ideas from universities, research institutes and professionals in the medical field and great support from the Singapore government. By applying our business model and expertise in incubation beyond Israel, we can tap the growth opportunities in Singapore and the wider Asia-Pacific region, nurture the development of innovative technologies in the healthcare sector, and play a larger role in improving the human condition."*

Commenting on the partnership, Ms. Anna Maria Braun, director of Trendlines Medical Singapore, and President of B. Braun Asia Pacific, said, *"Asia is a strategic area of growth for B. Braun, given its dynamic and innovative environment for medical technology start-up companies. By continually sharing expertise in dialogue with our partners, B. Braun aims to protect and improve the health of people around the world. I am delighted with the forging of this partnership between B. Braun and Trendlines Medical Singapore, and look forward to the creation and advancement of innovative medical solutions to benefit customers and patients in Asia Pacific and the world."*

- The End -

Issued for and on behalf of The Trendlines Group Ltd.

By Financial PR Pte Ltd.

For more information, please contact:

Romil SINGH / Reyna MEI

romil@financialpr.com.sg / reyna@financialpr.com.sg

Tel: (65) 6438 2990, Fax: (65) 6438 0064

About B. Braun

With over 56,000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive - and in turn improves people's health around the world. In 2015, the group generated sales of approximately €6.13 billion.

www.bbraun.com

About The Trendlines Group Ltd.

[Trendlines](#) is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines is traded on the Singapore Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.